VELCADE Administered by subcutaneous injection — Competitive Intelligence Brief

VELCADE Administered by subcutaneous injection (VELCADE Administered by subcutaneous injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

phase 3 Proteasome inhibitor Proteasome Oncology Small molecule

Target snapshot

VELCADE Administered by subcutaneous injection (VELCADE Administered by subcutaneous injection) — Millennium Pharmaceuticals, Inc.. VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VELCADE Administered by subcutaneous injection TARGET	VELCADE Administered by subcutaneous injection	Millennium Pharmaceuticals, Inc.	phase 3	Proteasome inhibitor	Proteasome
Ninlaro	IXAZOMIB	Takeda	marketed	Proteasome Inhibitor	Proteasome subunit beta type-5	2015-01-01
Kyprolis	carfilzomib	Amgen	marketed	Proteasome Inhibitor [EPC]	Proteasome subunit beta type-5	2012-01-01
Velcade	bortezomib	Shilpa	marketed	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
Bortezomib (B)	Bortezomib (B)	National Cancer Institute (NCI)	marketed	Proteasome inhibitor	26S proteasome
Kyprolis	Kyprolis	Black Sea Hematology Association	marketed		Cathepsin B, Glutathione S-transferase omega-1, Proteasome subunit beta type-10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-11-03 — Velcade · 8962572 · Formulation · US
• 2042-09-23 — Velcade · 11752164 · Method of Use · US
• 2042-09-23 — Velcade · 11679119 · Method of Use · US
• 2042-09-23 — Velcade · 12005069 · Formulation · US

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class